iBio Bilan de santé

Santé financière contrôle des critères 1/6

iBio possède un total de capitaux propres de $9.2M et une dette totale de $13.1M, ce qui porte son ratio d'endettement à 142.8%. Son actif total et son passif total sont $34.0M et de $24.8M.

Informations clés

142.8%

Ratio d'endettement

US$13.14m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$2.79m
Fonds propres	US$9.20m
Total du passif	US$24.83m
Total des actifs	US$34.02m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 0JV0 ( $19.7M ) ne couvrent pas ses passifs à court terme ( $21.6M ).

Passif à long terme: Les actifs à court terme de 0JV0 ( $19.7M ) dépassent ses passifs à long terme ( $3.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 0JV0 ( 112.5% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de 0JV0 est passé de 0% à 142.8% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 0JV0 dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 0JV0 dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 20.9 % chaque année

iBio Bilan de santé

Santé financière contrôle des critères 1/6

Informations clés

Mises à jour récentes de la santé financière

iBio, Inc. announced delayed annual 10-K filing

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio, Inc. announced delayed annual 10-K filing

Recent updates

iBio, Inc., Annual General Meeting, Nov 21, 2024

iBio, Inc. Announces the Appointment of Kristi Sarno as Senior Vice President of Business Development

Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million.

iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC

iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million.

New major risk - Financial position

iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx

iBio, Inc., Annual General Meeting, Nov 27, 2023

New major risk - Market cap size

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx

Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022)

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022)

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022

iBio, Inc. Announces Executive Changes

iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board

iBio, Inc. Appoints William D. (Chip) Clark as Chairman

iBio, Inc., Annual General Meeting, Dec 08, 2022

iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies'

iBio, Inc. announced delayed annual 10-K filing

iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Third quarter 2022 earnings released: US$0.057 loss per share (vs US$0.036 loss in 3Q 2021)

iBio, Inc. to Report Q3, 2022 Results on May 12, 2022

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022

iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202

iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2

First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021)

High number of new directors

iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022

High number of new directors

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020)

iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program

iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.69 loss in 2Q 2020)

Revenue beats expectations

iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021

iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021

New 90-day high: €1.73

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

New 90-day low: €0.88

iBio, Inc. Announces Resignation of Robert L. Erwin as President

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million.

iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020

iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020

iBio, Inc. Announces Appointment of Members to Committees

iBio, Inc. Appoints Gary Sender to Its Board of Directors

iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

iBio, Inc. announced delayed annual 10-K filing

New 90-day high - €3.12

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines